title: Therapeutic advances for primary biliary cholangitis: the old and the new.
abstract: Primary biliary cholangitis (PBC, primary biliary cirrhosis) is an autoimmune cholestatic liver disease characterized by chronic nonsuppurative destructive cholangitis and the presence of serum antimitochondrial antibodies. Ursodeoxycholic acid is the only drug approved by the US Food and Drug Administration to treat PBC. However, one-third of patients show incomplete responses to ursodeoxycholic acid and a poor prognosis. A number of old and new medications have been used in these patients, such as fibrates, glucocorticoids, immunosuppressants, obeticholic acid, mesenchymal stem cells, biological agents (anti-interleukin-12, cytotoxic T-lymphocyte antigen 4 immunoglobulin, anti-CD20), and antifibrotic drugs. This article reviews the therapeutic advances of these old and new medications in patients with PBC.
authors: Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Department of Rheumatology & Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
authors: Li
authors: L
authors: Wang
authors: Feng-Chun
authors: FC
authors: Zhang
authors: Xuan
authors: X
authors: Zhang
mesh_terms: D000069594:Abatacept / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D002635:Chenodeoxycholic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D002756:Cholagogues and Choleretics / Q000627:therapeutic use*; D016572:Cyclosporine / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D058607:Fibric Acids / Q000627:therapeutic use*; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007211:Indoles / Q000627:therapeutic use; D008105:Liver Cirrhosis, Biliary / Q000628:therapy*; D045164:Mesenchymal Stem Cell Transplantation; D008727:Methotrexate / Q000627:therapeutic use; D009173:Mycophenolic Acid / Q000627:therapeutic use; D011728:Pyridones / Q000627:therapeutic use; D000069283:Rituximab / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use*; D000069549:Ustekinumab / Q000627:therapeutic use
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D002756:Cholagogues and Choleretics; D004791:Enzyme Inhibitors; D058607:Fibric Acids; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D007211:Indoles; D011728:Pyridones; C464660:obeticholic acid; D002635:Chenodeoxycholic Acid; D000069283:Rituximab; D014580:Ursodeoxycholic Acid; D000069594:Abatacept; D016572:Cyclosporine; C093844:pirfenidone; D000069549:Ustekinumab; C530716:nintedanib; D009173:Mycophenolic Acid; D001379:Azathioprine; D016559:Tacrolimus; D008727:Methotrexate